Exchange: NASDAQ·Updated 07:50 PM EST
ENSC logo

ENSC Ensysce Biosciences Inc

$0.36
$0.0006
(0.17%)
Today
Closed $0.36
$0.0499
(13.86%)
After Hours
Reported EarningsMay 13
Mkt Cap$7M
Vol83,391.00

About ENSC

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
63

Bullish Sentiment

How do you feel about ENSC?

Chicamann
$ENSC By not releasing the results to the Phase 3 trials we just have to assume that the results of your medication showed that it stunts chronic pain by killing its patient with cancer. The only reason I bought this stock was because someone who knew Lynn took the time to tell me great things about her and her company. I wish they had instead taken that time to simply stab me as many times as they possibly could. I would be in a better position in that case than I am holding shares of ENSC.
8
Big_Zack22
$ENSC Think about it: when ENSC went public in 2021, it had 281 million shares outstanding. Five years later, the company has failed to deliver on what it promised the market. After three reverse splits, there are now only about 19 million shares left. ENSC recently merged with Cy Biopharma, and since then, management keeps talking about Phase 2 of CYBIO-001 while avoiding any discussion of its main product, which was supposed to be completed by August 2026. Now we’re looking at another 400 million shares being issued, which could lead to three more reverse splits. No wonder investors feel misled.
1
3
Julian_759
$ENSC any of the bears or anyone who is knowledgeable can educate me why institutional investing is 54% if the company is gonna fail? Bob has a million shares and what happens to sp if the phase 3 is announced now, squeeze? Since shares available are lesser? We are retail after all. Believe institutions and insiders have better knowledge
1
3
EnsysceBiosciences
$ENSC Our third-quarter 2026 results reflect a transformative period for Ensysce, highlighted by the acquisition of Cy Biopharma, the addition of CY200 as our lead clinical asset, and a significantly strengthened balance sheet to support ongoing pipeline advancement. We ended September with $29.7 million in cash and cash equivalents, up from $4.3 million at year-end 2025, driven by financing proceeds and cash acquired through the transaction. This enhanced capital position provides greater flexibility as we execute on our clinical and corporate development objectives. Federal grant funding increased to $2.2 million during the quarter, compared with $0.5 million in the prior-year period, reflecting continued external validation and support for our development programs. Operating expenses included $3.2 million in R&D expenses and $1.6 million in G&A expenses, underscoring our focus on advancing key pipeline assets while maintaining disciplined operations.
2
Big_Zack22
$ENSC No milestones, no indication on what they had done and where they're heading us to. We are like the f####g blind guys in a labyrinth. Step Lynn down definitely.
6
BULLISH1975
$ENSC you sound like a hero now!!! well done BUTT the founder mr Gower added about 400k worth at over 50 cents last quarter if i recall!!! why you may be the one crying in a few months or years! food for thought!!!! science works- big pharma will buy this company in next 2 years IMO and it will be hundreds of millions or possible B GL dyor
1
3
StockDreamin
$ENSC You know they post on here only as damage control...right before or after it gets worse and worse...thats why I'd rather they didnt...it's insulting! We know how to look up our own info.
5
Sunnybhargava
$ENSC what happened to pain interim and overdose data. Which you started long back. Same stupid stuff you put every other day doesn’t make sense what are you doing to increase shareholder value which Lynn said last Feb when stock was trading .70-1$
1
2
Turan_1
$ENSC I have perhaps been one of the most patient and polite people on this forum, but even my patience is finally wearing thin. What you are doing here is an absolute outrage—constantly repeating the same things over and over!
5
Jlh50
$ENSC I don’t understand what happened with interim results. At the end of January, they announced that 50% of target enrollment for interim had been reached.So that was about 7 weeks after the trial started. So they should have reached 100% around the end of March and even if we double the time, then sometime in May. Here it is end of November and not a peep. Why in the world would you announce 50% enrollment if you didn’t intend to announce 100%. Not to mention that the trial should be done by now. Communication is really lacking here.
3
StockDreamin
$ENSC Bravo! .20 x 30 = 6.00 Hold 10 days for 4.00 compliance then tank to analyst rating of 2.00 What a bright future. Anyone know where I can find some pain killers and mushrooms?!
3
Bernic88
$ENSC How many reverse splits have you already been through here? The next one certainly won’t be the last. Or, to put it another way: how many outstanding shares will the company have soon? It’s always the same old game. Companies like this are only good for gambling—nothing more.In the past, you used to mock critics here and resort to insults. That’s karma coming back around.
1
1
StockDreamin
$ENSC February closing in! None of that magical "organic growth" no overseas investors, running out of cash, administration wants more raises, no reports, no progress, no leadership, no concern for shareholders!
4
EnsysceBiosciences
$ENSC Cantor Fitzgerald’s coverage brings an independent perspective to Ensysce’s CY200 program’s clinical and commercial potential. Its Overweight rating and $2 price target reflect three considerations: A differentiated therapeutic approach. CY200 is being developed to address the underlying neurobiology of Complex Regional Pain Syndrome (CRPS), rather than relying on symptom management. An encouraging early clinical signal. Cantor highlighted patient data showing a 50% responder rate, while recognizing that controlled evidence remains essential to establish efficacy and durability. A meaningful unmet medical need. With no FDA-approved treatments specifically for CRPS, positive Phase 2 results could help establish CY200’s therapeutic relevance and inform its longer-term commercial potential. Beyond the price target, this coverage offers an external framework for assessing CY200’s differentiation, evidence needed and the potential value of advancing clinical development.
1
1
Big_Zack22
$ENSC very disgusting. I'll write taxes loss and stay on sideways until Lynn leaves this company.
3
EnsysceBiosciences
$ENSC The third quarter marked a significant strategic milestone with the completion of the Cy Biopharma acquisition, establishing CY200 as Ensysce’s lead development candidate for Complex Regional Pain Syndrome (CRPS), a debilitating chronic pain condition for which there are currently no FDA-approved therapies. CY200 is a psilocybin-predominant botanical drug candidate designed to address the underlying neurobiological mechanisms associated with CRPS rather than solely managing symptoms. Importantly, its active ingredient has received FDA Orphan Drug Designation, supporting the potential for a differentiated regulatory and development pathway. In September, we submitted CYBIO 001, our proposed UK Phase 2a clinical study, for combined review by the Medicines and Healthcare products Regulatory Agency (MHRA) and a research ethics committee.
1
Sunnybhargava
$ENSC where is the interim review of phase 3 pain medicine which was 50% enrollment done for interim in January. It’s cheating investors while you guys holding good interim results and doing RS. Show the data and let stock run rather then pinning it every day. It’s stock manipulation.
3
Chicamann
$ENSC Guys please, enough of the doom and gloom. Let’s try talking about things we’re grateful for. I’ll start, I’m grateful that because of ENSC, I will not be paying capital gains taxes this year. Now it’s your turn.
1
Sunnybhargava
$ENSC should have sold at .60. They talking about overdoses study. But never talk about pain interim which enrolled 50% in January and interim is overdue. Lynn never did anything for shareholders value. Her politics are all trash to eat retail investors always. Cheat shareholders. Now it’s getting frustrating.
3
Matte73
$ENSC AI! No, that is not correct. Ensysce Biosciences does not have 400 million shares outstanding. The actual number of outstanding common shares is significantly lower, at approximately 19.46 million shares. However, there is a specific reason why the 400 million figure is circulating: Shareholders planning to sell: SEC filings from late October 2026 show that existing shareholders have registered plans to potentially sell up to 433.91 million shares in the future. What does this mean? This typically involves the registration of underlying shares that could be issued if investors choose to exercise their warrants, convertibles, or financial agreements. Therefore, these are not shares available on the market today, but rather a potential future dilution. In summary: The shares actually trading on the stock market today amount to just under 20 million. The rumor of 400 million stems from a registration document for potential future sales by financial partners.
3

Advertisement|Remove ads.